374 related articles for article (PubMed ID: 32844337)
1. Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure.
Razeghian-Jahromi I; Zibaeenezhad MJ; Lu Z; Zahra E; Mahboobeh R; Lionetti V
Heart Fail Rev; 2021 Mar; 26(2):371-380. PubMed ID: 32844337
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
3. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA
Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.
Oz M; Lorke DE; Kabbani N
Pharmacol Ther; 2021 May; 221():107750. PubMed ID: 33275999
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.
Tomasoni D; Italia L; Adamo M; Inciardi RM; Lombardi CM; Solomon SD; Metra M
Eur J Heart Fail; 2020 Jun; 22(6):957-966. PubMed ID: 32412156
[TBL] [Abstract][Full Text] [Related]
6. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.
Matsuzawa Y; Kimura K; Ogawa H; Tamura K
Hypertens Res; 2022 Jul; 45(7):1147-1153. PubMed ID: 35581498
[TBL] [Abstract][Full Text] [Related]
7. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
Lebek S; Tafelmeier M; Messmann R; Provaznik Z; Schmid C; Maier LS; Birner C; Arzt M; Wagner S
Eur J Heart Fail; 2020 Dec; 22(12):2248-2257. PubMed ID: 33017071
[TBL] [Abstract][Full Text] [Related]
9. Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation.
Augustine R; S A; Nayeem A; Salam SA; Augustine P; Dan P; Maureira P; Mraiche F; Gentile C; Hansbro PM; McClements L; Hasan A
Chem Biol Interact; 2022 Jan; 351():109738. PubMed ID: 34740598
[TBL] [Abstract][Full Text] [Related]
10. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.
Savoia C; Volpe M; Kreutz R
Circ Res; 2021 Apr; 128(7):1062-1079. PubMed ID: 33793331
[TBL] [Abstract][Full Text] [Related]
11. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
12. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
Edmonston DL; South AM; Sparks MA; Cohen JB
Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 and renin-angiotensin system modulators: what do we know so far?
de la Cruz A; Ashraf S; Vittorio TJ; Bella JN
Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):743-748. PubMed ID: 32842817
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
Dworakowska D; Grossman AB
J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235
[TBL] [Abstract][Full Text] [Related]
16. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19.
Pedrosa MA; Valenzuela R; Garrido-Gil P; Labandeira CM; Navarro G; Franco R; Labandeira-Garcia JL; Rodriguez-Perez AI
Clin Sci (Lond); 2021 Feb; 135(3):465-481. PubMed ID: 33479758
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.
Vieira C; Nery L; Martins L; Jabour L; Dias R; Simões E Silva AC
Curr Drug Targets; 2021; 22(3):254-281. PubMed ID: 33081670
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
Brojakowska A; Narula J; Shimony R; Bander J
J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2.
Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F
Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies.
Kai H; Kai M; Niiyama H; Okina N; Sasaki M; Maeda T; Katoh A
Hypertens Res; 2021 Aug; 44(8):955-968. PubMed ID: 33750913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
